Advanced search
Publication Cover
Leukemia & Lymphoma Volume 51, 2010 - Issue 7
Submit an article Journal homepage
227
Views
13
CrossRef citations to date
0
Altmetric
Original Articles: Clinical

Phase II study of immunomodulation with granulocyte-macrophage colony-stimulating factor, interleukin-2, and rituximab following autologous stem cell transplant in patients with relapsed or refractory lymphomas

Xavier PoiréDepartment of Medicine, Section of Hematology/Oncology and University of Chicago Comprehensive Research Center, University of Chicago Medical Center, Chicago, IL, USA
,
Justin KlineDepartment of Medicine, Section of Hematology/Oncology and University of Chicago Comprehensive Research Center, University of Chicago Medical Center, Chicago, IL, USACorrespondence[email protected]
,
David GrinblattHematology, Northshore University HealthSystems, Evanston, IL, USA
,
Todd ZimmermanDepartment of Medicine, Section of Hematology/Oncology and University of Chicago Comprehensive Research Center, University of Chicago Medical Center, Chicago, IL, USA
,
Kathy ConnerDepartment of Medicine, Section of Hematology/Oncology and University of Chicago Comprehensive Research Center, University of Chicago Medical Center, Chicago, IL, USA
,
Carolyn MuhsDepartment of Medicine, Section of Hematology/Oncology and University of Chicago Comprehensive Research Center, University of Chicago Medical Center, Chicago, IL, USA
,
Thomas GajewskiDepartment of Medicine, Section of Hematology/Oncology and University of Chicago Comprehensive Research Center, University of Chicago Medical Center, Chicago, IL, USA
,
Koen Van BesienDepartment of Medicine, Section of Hematology/Oncology and University of Chicago Comprehensive Research Center, University of Chicago Medical Center, Chicago, IL, USA
&
Sonali M. SmithDepartment of Medicine, Section of Hematology/Oncology and University of Chicago Comprehensive Research Center, University of Chicago Medical Center, Chicago, IL, USA
 show all
Pages 1241-1250 | Received 15 Dec 2009, Accepted 15 Apr 2010, Published online: 24 May 2010

Citations (13)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Eric van den Neste, Rémi Letestu, Thérèse Aurran-Schleinitz, Loïc Ysebaert, Pierre Feugier, Stéphane Leprêtre & Caroline Dartigeas. (2012) Post-remission intervention with alemtuzumab or rituximab to eradicate minimal residual disease in chronic lymphocytic leukemia: where do we stand?. Leukemia & Lymphoma 53:3, pages 362-370.
Read now

Articles from other publishers (12)

Didier Dréau, Laura Jeffords Moore, Mike Wu, Lopa Das Roy, Lloye Dillion, Travis Porter, Rahul Puri, Noor Momin, K. Dane Wittrup & Pinku Mukherjee. (2019) Combining the Specific Anti-MUC1 Antibody TAB004 and Lip-MSA-IL-2 Limits Pancreatic Cancer Progression in Immune Competent Murine Models of Pancreatic Ductal Adenocarcinoma. Frontiers in Oncology 9.
Crossref
John M. WrangleAlicia PattersonC. Bryce JohnsonDaniel J. NeitzkeShikhar MehrotraChadrick E. DenlingerChrystal M. PaulosZihai LiDavid J. ColeMark P. Rubinstein. (2018) IL-2 and Beyond in Cancer Immunotherapy. Journal of Interferon & Cytokine Research 38:2, pages 45-68.
Crossref
Jean-Baptiste Gorin, Jérémie Ménager, Yannick Guilloux, Jean-François Chatal, Joëlle Gaschet & Michel Chérel. 2018. Resistance to Ibritumomab in Lymphoma. Resistance to Ibritumomab in Lymphoma 119 137 .
Ravi Maddaly, Aishwarya Subramaniyan & Harini Balasubramanian. (2017) Cancer Cytokines and the Relevance of 3D Cultures for Studying Those Implicated in Human Cancers. Journal of Cellular Biochemistry 118:9, pages 2544-2558.
Crossref
Pan Jiang, Yan Zhang, Steve J Archibald & Hua Wang. (2015) Adoptive cell transfer after chemotherapy enhances survival in patients with resectable HNSCC. International Immunopharmacology 28:1, pages 208-214.
Crossref
Eric?F. Zhu, Shuning?A. Gai, Cary?F. Opel, Byron?H. Kwan, Rishi Surana, Martin?C. Mihm, Monique?J. Kauke, Kelly?D. Moynihan, Alessandro Angelini, Robert?T. Williams, Matthias?T. Stephan, Jacob?S. Kim, Michael?B. Yaffe, Darrell?J. Irvine, Louis?M. Weiner, Glenn Dranoff & K.?Dane Wittrup. (2015) Synergistic Innate and Adaptive Immune Response to Combination Immunotherapy with Anti-Tumor Antigen Antibodies and Extended Serum Half-Life IL-2. Cancer Cell 27:4, pages 489-501.
Crossref
Ana Márquez, Cristina Lucía Dávila-Fajardo, Gema Robledo, José Luis Callejas Rubio, Enrique de Ramón Garrido, Francisco J. García-Hernández, Rocío González-León, Raquel Ríos-Fernández, José Cabeza Barrera, Ma. Francisca González-Escribano, Ma. Teresa Camps García, Ma. Jesús Castillo Palma, Ma. del Mar Ayala, Norberto Ortego-Centeno & Javier Martín. (2013) IL2/IL21 region polymorphism influences response to rituximab in systemic lupus erythematosus patients. Molecular Biology Reports 40:8, pages 4851-4856.
Crossref
Bo Yang, Xue‐chun Lu, Rui‐li Yu, Xiao‐hua Chi, Yang Liu, Yao Wang, Han‐ren Dai, Hong‐li Zhu, Li‐li Cai & Wei‐dong Han. (2011) Repeated transfusions of autologous cytokine‐induced killer cells for treatment of haematological malignancies in elderly patients: a pilot clinical trial. Hematological Oncology 30:3, pages 115-122.
Crossref
Haihan SongLei ChenZhanshan ChaJianwen Bai. (2012) Interleukin 2 Gene Polymorphisms Are Associated with Non-Hodgkin Lymphoma. DNA and Cell Biology 31:7, pages 1279-1284.
Crossref
Xue-chun Lu, Bo Yang, Rui-li Yu, Xiao-hua Chi, Shuai Tuo, Chao-wei Tuo, Hong-li Zhu, Yao Wang, Chao-guang Jiang, Xiao-bing Fu, Yang Yang, Yang Liu, Shan-qian Yao, Han-ren Dai, Li-li Cai, Bing-jun Li & Wei-dong Han. (2011) Clinical Study of Autologous Cytokine-Induced Killer Cells for the Treatment of Elderly Patients with Diffuse Large B-Cell Lymphoma. Cell Biochemistry and Biophysics 62:1, pages 257-265.
Crossref
Esther Moga, Elisabet Cantó, Silvia Vidal, Cándido Juarez, Jorge Sierra & Javier Briones. (2011) Interleukin-15 enhances rituximab-dependent cytotoxicity against chronic lymphocytic leukemia cells and overcomes transforming growth factor beta-mediated immunosuppression. Experimental Hematology 39:11, pages 1064-1071.
Crossref
. (2011) Current World Literature. Current Opinion in Oncology 23:2, pages 227-234.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.